Oncotarget

Reviews:

Targeting Mnks for Cancer Therapy

Jinqiang Hou, Frankie Kam, Christopher G Proud and Shudong Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2012; 3:118-131. https://doi.org/10.18632/oncotarget.453

Metrics: PDF 3778 views  |   HTML 4699 views  |   ?  


Abstract

Jinqiang Hou1, Frankie Lam1, Christopher Proud2 and Shudong Wang1

1 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

2 Centre for Biological Sciences, University of Southampton, Southampton, UK

Received: February 16, 2012; Accepted: February 29, 2012; Published: March 3, 2012;

Keywords: eIF4E, Mnk, Ras, Raf, MAPK, Akt, PI3K, mTOR, Targeted Cancer Therapy, Structure based drug design, Mnk Inhibitors

Correspondence:

Shudong Wang,

Abstract

Deregulation of protein synthesis is a common event in human cancer and a key player in translational control is eIF4E. Elevated expression levels of eIF4E promote cancer development and progression. Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer. The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK. While the phosphorylation event is necessary for oncogenic transformation, it seems to be dispensable for normal development. Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective anti-cancer strategy. Strong circumstantial evidence indicates that Mnk inhibition presents attractive therapeutic potential, but the lack of selective Mnk inhibitors has so far confounded pharmacological target validation and clinical development.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 453